Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets

References

• Juliusson G, Hough R. Leukemia. Prog Tumor Res. 2016;43:87–100.
   PubMed Web of Science ®Google Scholar
• Mastelaro de Rezende M, Ferreira AT, Paredes-Gamero EJ Leukemia stem cell immunophenotyping tool for diagnostic, prognosis, and therapeutics. J Cell Physiol. 2020;235(6):4989–4998.
   PubMed Web of Science ®Google Scholar
• American Cancer Society Cancer Statistics Center. http://cancerstatisticscenter.cancer.org. Cited 2022 Oct 10
   Google Scholar
• Gubin MM, Artyomov MN, Mardis ER, et al. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125(9):3413–3421
   PubMed Web of Science ®Google Scholar
• Newsome BW, Ernstoff MS The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol. 2008;66:6–19
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP The future of immune checkpoint therapy. Science. 2015;348:56–61.
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2021;16:223–249.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. PNAS. 2002;99(19):12293–12297
   PubMed Web of Science ®Google Scholar
• Barsan V, Ramakrishna S, Davis KL Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia. Curr Oncol Rep. 2020;22:11–19.
   PubMed Web of Science ®Google Scholar
• Lichtenegger FS, Krupka C, Köhnke T, et al. Immunotherapy for acute myeloid leukemia. Semin Hematol. 2015;52(3):207–214.
   PubMed Web of Science ®Google Scholar
• Aoki J, Kanamori H, Tanaka M, et al. Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. Am J Hematol. 2016;91(3),302–307
   PubMed Web of Science ®Google Scholar
• Takami A Hematopoietic stem cell transplantation for acute myeloid leukemia. Int J Hematol. 2018;107(5):513–518
   PubMed Web of Science ®Google Scholar
• Lessi F, Laurino M, Papayannidis C, et al. Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study. Biomedicines. 2021;9(8):972
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. NEJM 2020;383(7):617–629
   PubMed Web of Science ®Google Scholar
• Gupta PB, Chaffer CL, Weinberg RA Cancer stem cells: mirage or reality? Nat Med. 2009;15:1010–1012.
   PubMed Web of Science ®Google Scholar
• Gurska LM, Ames K, Gritsman K Signaling Pathways in Leukemic Stem Cells. Adv Exp Med Biol. 2019;1143:1–39
   PubMed Web of Science ®Google Scholar
• Lipman NS, Jackson LR, Trudel LJ, et al. Monoclonal Versus Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information Resources. ILAR J. 2005;46(3):258–268
   PubMed Web of Science ®Google Scholar
• Buss NAPS, Henderson SJ, McFarlane M, et al. Monoclonal antibody therapeutics: History and future. Curr Opin Pharmacol. 2012;12(5):615–622.
   PubMed Web of Science ®Google Scholar
• Porter RR Separation and Isolation of Fractions of Rabbit Gamma-Globulin Containing the Antibody and Antigenic Combining Sites. Nat Cell Biol. 1958;182:670–671.
   Google Scholar
• Köhler G, Milstein C Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–497
   PubMed Web of Science ®Google Scholar
• Redman JM, Hill EM, AlDeghaither D, et al. Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol. 2015;67(2):28–45
   PubMed Web of Science ®Google Scholar
• Williams BA, Law A, Hunyadkurti J, et al. Antibody therapies for acute myeloid leukemia: Unconjugated, toxin-conjugated, radio-conjugated and multivalent formats. J Clin Med. 2019;8(8):1261.
   PubMed Web of Science ®Google Scholar
• Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother. 2013;62:217–223
   PubMed Web of Science ®Google Scholar
• Kalim M, Chen J, Wang S, et al. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther. 2017;11:2265–2276.
   PubMed Web of Science ®Google Scholar
• Walter RB Brief overview of antibody-drug conjugate therapy for acute leukemia. Expert Opin Biol Ther. 2021;21(7):795–799.
   PubMed Web of Science ®Google Scholar
• Czajkowsky DM, Hu J, Shao Z, et al. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med. 2012;4(10):1015–1028
   PubMed Web of Science ®Google Scholar
• Pelosi E, Castelli G, Testa U Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells. Blood Cells Mol Dis. 2015;55(4):336–346
   PubMed Web of Science ®Google Scholar
• Taylor VC, Buckley CD, Douglas M, et al. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem. 1999;274:11505–11512.
   PubMed Web of Science ®Google Scholar
• Ulyanova T, Blasioli J, Woodford-Thomas TA, et al. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol. 1999;29:3440–3449.
   PubMed Web of Science ®Google Scholar
• Paul SP, Taylor LS, Stansbury EK, et al. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood. 2000;96:483–490
   PubMed Web of Science ®Google Scholar
• Orr SJ, Morgan NM, Elliott J, et al. CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood. 2007;109:1061–1068
   PubMed Web of Science ®Google Scholar
• Crocker PR, Paulson JC, Varki A Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7(4):255–266.
   PubMed Web of Science ®Google Scholar
• Pearce D, Taussig D, Bonnet D Implications of the Expression of Myeloid Markers on Normal and Leukemic Stem Cells. Cell Cycle. 2006;5(3):271–273
   PubMed Web of Science ®Google Scholar
• Griffin JD, Linch D, Sabbath K, et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8(4):521–534
   PubMed Web of Science ®Google Scholar
• Vercauteren S, Zapf R, Sutherland H Primitive AML progenitors from most CD34(+) patients lack CD33 expression but progenitors from many CD34(-) AML patients express CD33. Cytotherapy. 2007;9(2):194–204
   PubMed Web of Science ®Google Scholar
• Selby C, Yacko LR, Glode AE Gemtuzumab Ozogamicin: Back Again. J Adv Pract Oncol. 2019;10(1):68–82
   PubMedGoogle Scholar
• Baron J, Wang ES Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549–559
   PubMed Web of Science ®Google Scholar
• Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–1496
   PubMed Web of Science ®Google Scholar
• Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and post consolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854–4860
   PubMed Web of Science ®Google Scholar
• Gottardi M, Sperotto A, Di Rorà AGL, et al. Gemtuzumab ozogamicin in acute myeloid leukemia: Past, present and future. Minerva Med. 2020;111 (5):395–410.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan D, et al. Identification of Patients with Acute Myeloblastic Leukemia Who Benefit from the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial. J Clin oncol. 2011;29(4):369–377
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin oncol. 2012;30(32):3924–3931
   PubMed Web of Science ®Google Scholar
• Lambert J, Pautas C, Terré C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104(1):113–119
   PubMed Web of Science ®Google Scholar
• Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021–3032
   PubMed Web of Science ®Google Scholar
• Stein EM, Walter RB, Erba HP, et al. A Phase 1 Trial of Vadastuximab Talirine as Monotherapy in Patients with CD33-positive Acute Myeloid Leukemia. Blood. 2018;131:387–396
   PubMed Web of Science ®Google Scholar
• Sutherland MK, Yu C, Lewis TS, et al. Anti-Leukemic Activity of Lintuzumab (Sgn-33) in Preclinical Models of Acute Myeloid Leukemia. MAbs. 2009;1:481–490
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Brandwein J, Stone R, et al. Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination with Chemotherapy, Versus Chemotherapy Alone in Patients with Refractory or First-Relapsed Acute Myeloid Leukemia. J Clin Oncol. 2005;23:4110–4116
   PubMed Web of Science ®Google Scholar
• Vasu S, He S, Cheney C Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. Blood. 2016;127(23):2879–2889
   PubMed Web of Science ®Google Scholar
• Vasu S, Altman JK, Uy GL, et al. A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia. Haematologica. 2022;107(3):770–773
   PubMed Web of Science ®Google Scholar
• Liu K, Zhu M, Huang Y, et al. CD123 and its potential clinical application in leukemias. Life Sci. 2015;122:59–64.
   PubMed Web of Science ®Google Scholar
• Barry SC, Korpelainen E, Sun Q, et al. Roles of the N and C terminal domains of the interleukin-3 receptor α chain in receptor function. Blood. 1997;89(3):842–852
   PubMed Web of Science ®Google Scholar
• Testa U, Pelosi E, Frankel A CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2(1):4
   PubMedGoogle Scholar
• Muñoz L, Nomdedeu JF, López O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86:1261–1269
   PubMed Web of Science ®Google Scholar
• Haubner S, Perna F, Köhnke T, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64–74
   PubMed Web of Science ®Google Scholar
• Busfield SJ, Biondo M, Wong M, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014;28:2213–2221
   PubMed Web of Science ®Google Scholar
• Montesinos P, Roboz GJ, Bulabois CE, et al. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia. 2021;35(1):62–74
   PubMed Web of Science ®Google Scholar
• Smith BD, Roboz GJ, Walter RB, et al. First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse. Blood. 2014;124(21):120
   Google Scholar
• Kovtun Y, Jones GE, Adams S, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2(8):848–858
   PubMed Web of Science ®Google Scholar
• Daver NG, Sweet KL, Montesinos P, et al. A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. Blood. 2020;136(Supplement 1):50–51
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. NEJM. 2019;380(17):1628–1637
   PubMed Web of Science ®Google Scholar
• Togami K, Pastika T, Stephansky J, et al. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019;129(11):5005–5019
   PubMed Web of Science ®Google Scholar
• Montero J, Stephansky J, Cai T, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017;7(2):156–164
   PubMed Web of Science ®Google Scholar
• Lane AA, Stein AS, Garcia JS, et al. Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN. Blood. 2021;138(Supplement 1):2346
   Google Scholar
• Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–285.
   PubMed Web of Science ®Google Scholar
• Chao MP, Weissman IL, Majeti R The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24:225–232
   PubMed Web of Science ®Google Scholar
• Chao MP, Takimoto CH, Feng DD, et al. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies. Front Oncol. 2020;9:1380.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L, Zhao F, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One. 2015;10:e0137345
   PubMed Web of Science ®Google Scholar
• Vyas P, Knapper S, Kelly R, et al. Initial phase 1 results of the first-in-class anti-CD47 antibody HU5F9-G4 in relapsed/refractory acute myeloid leukemia patients. Eur Hematol Assoc Meeting. 2018;23(Abstract):232
   Google Scholar
• Daver NG, Vyas P, Kambhampati S, et al. S132: Tolerability And Efficacy Of The First-In-Class Anti-Cd47 Antibody Magrolimab Combined With Azacitidine In Frontline Patients With Tp53-Mutated Acute Myeloid Leukemia: Phase 1b Results. Hemasphere. 2022;6(Suppl):33–34
   Google Scholar
• Oronsky B, Carter C, Reid T, et al. Just eat it: A review of CD47 and SIRP-α antagonism. Semin Oncol. 2020;47(2):117–124.
   PubMed Web of Science ®Google Scholar
• Petrova PS, Viller NN, Wong M, et al. TTI-621 (SIRPalphaFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2017;23:1068–79
   PubMed Web of Science ®Google Scholar
• Daver NG, Maris M, Ramchandren R, et al. Pb1820: Cd47-Blocker Tti-622 Combined With Azacitidine In Patients With Tp53-Mutated Acute Myeloid Leukemia (Aml) And With Azacitidine + Venetoclax In Elderly Or Unfit Patients With Tp53-Wildtype Aml. Hemasphere. 2022;6(Suppl.):1700–1701.
   Google Scholar
• Chan H, Trout C, Mikolon D, et al. Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab. Blood. 2021;138:2271.
   Web of Science ®Google Scholar
• Narla RK, Modi H, Bauer D, et al. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody. Cancer Immunol Immunother. 2022;71:473–89
   PubMed Web of Science ®Google Scholar
• Hintzen RQ, Lens SM, Beckmann MP, et al. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol. 1994;152(4):1762–1773.
   PubMed Web of Science ®Google Scholar
• Wajant H Therapeutic targeting of CD70 and CD27. Expert Opin Ther Targets. 2016;20(8):959–973.
   PubMed Web of Science ®Google Scholar
• Riether C, Schürch CM, Bührer ED, et al. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med. 2017;214(2):359–380.
   PubMed Web of Science ®Google Scholar
• Riether C, Pabst T, Höpner S, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020;26(9):1459–1467.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Pabst T, Aribi A, et al. Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study. Blood. 2021;138(Supplement 1):369.
   Google Scholar
• Chiffoleau E C-type lectin-like receptors as emerging orchestrators of sterile inflammation represent potential therapeutic targets. Front Immunol. 2018;9:227
   PubMed Web of Science ®Google Scholar
• Neumann K, Castineiras-Vilarino M, Hockendorf U, et al. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Immunity. 2014;40:389–99
   PubMed Web of Science ®Google Scholar
• Bakker AB, van den Oudenrijn S, Bakker AQ, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64:8443–50
   PubMed Web of Science ®Google Scholar
• Marshall AS, Willment JA, Lin HH, et al. Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. J Biol Chem. 2004;279:14792–802.
   PubMed Web of Science ®Google Scholar
• Darwish NH, Sudha T, Godugu K, et al. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget. 2016;7:57811–57820.
   PubMedGoogle Scholar
• Chen CH, Floyd H, Olson NE, et al. Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production. Blood. 2006;107:1459–67.
   PubMed Web of Science ®Google Scholar
• Bill M, van Kooten Niekerk PB, Woll PS, et al. Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC 12A-related cancer stem cell biology. J Cell Mol Med. 2018;22:2311–8.
   PubMed Web of Science ®Google Scholar
• Zheng B, Yu SF, Rosario G, et al. An anti–CLL-1 antibody–drug conjugate for the treatment of acute myeloid leukemia. Clin Cancer Res. 2019;25(4):1358–1368.
   PubMed Web of Science ®Google Scholar
• Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131) I-anti-CD45antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94(4):1237–1247.
   PubMed Web of Science ®Google Scholar
• Gyurkocza B, Nath R, Seropian SE, et al. High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment and Tolerability in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Therapies. Tandem Meetings of ASTCT and CIBMTR, Salt Lake City, UT. 2022;22(Abstract):40.
   Google Scholar
• Monney L, Sabatos C, Gaglia J, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536–41
   PubMed Web of Science ®Google Scholar
• Sabatos C, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4:1102–10.
   PubMed Web of Science ®Google Scholar
• Tan J, Huang S, Huang J, et al. Increasing Tim-3+CD244+, Tim-3+CD57+, and Tim-3+PD-1+ T Cells in Patients with Acute Myeloid Leukemia. Asia Pac J Clin Oncol. 2020;16(3):137–141.
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Miyamoto T, Yuda J, et al. A TIM-3/Galectin-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemia Progression. Cell Stem Cell. 2016;17:341–52.
   Web of Science ®Google Scholar
• Goncalves Silva I, Ruegg L, Gibbs BF, et al. The Immune Receptor Tim-3 Acts as a Trafficker in a Tim-3/Galectin-9 Autocrine Loop in Human Myeloid Leukemia Cells. Oncoimmunology. 2016;5(7):e1195535.
   PubMed Web of Science ®Google Scholar
• Goncalves Silva I, Yasinska IM, Sakhnevych SS, et al. The Tim-3-Galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. EBioMedicine. 2017;22:44–57
   PubMed Web of Science ®Google Scholar
• Schwartz S, Patel N, Longmire T, et al. Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Immunother Adv. 2022;2(1):ltac019.
   PubMedGoogle Scholar
• Brunner AM, Esteve J, Porkka K, et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study. Blood. 2021;138(Supplement 1):244.
   Google Scholar
• Zeidan AM, Westermann J, Kovacsovics T, et al. AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia (ND AML). Clin Lymphoma Myeloma Leuk. 2022;22(Supplement 2):S255.
   Google Scholar
• Farber M, Chen Y, Arnold L, et al. Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis. Sci Rep. 2021;11:22062
   PubMed Web of Science ®Google Scholar
• Zhu C, Song Z, Wang A, et al. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Frontiers in Immunology. 2020;11:1771.
   PubMed Web of Science ®Google Scholar
• Rosnet O, Bühring HJ, Marchetto S, et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 1996;10(2):238–248.
   PubMed Web of Science ®Google Scholar
• Daver NG, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML. NEJM. 2019;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• Hofmann M, Große-Hovest L, Nübling T, et al. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia. 2012;26(6):1228–1237.
   PubMed Web of Science ®Google Scholar
• Heitmann JS, Dörfel D, Kayser S, et al. First-in-human phase I dose escalation and expansion study evaluating the Fc optimized FLT3 antibody Flysyn in acute myeloid leukemia patients with minimal residual disease. Blood. 2020;136:(Supplement 1):8–9.
   PubMedGoogle Scholar
• Morone S, Augeri S, Cuccioloni M, et al. Binding of CD157 protein to fibronectin regulates cell adhesion and spreading. Journal of Biological Chemistry. 2014;289(22):15588–15601.
   PubMed Web of Science ®Google Scholar
• Yakymiv Y, Augeri S, Bracci C, et al. CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1. Scientific Reports. 2021;11(1). DOI:10.1038/s41598-021-00733-5
   PubMed Web of Science ®Google Scholar
• Krupka C, Lichtenegger FS, Kohnke T, et al. Targeting CD157 in AML using a novel, Fc-engineered antibody construct. Oncotarget. 2017;8(22):35707–35717.
   PubMedGoogle Scholar
• Yakymiv Y, Augeri S, Fissolo G, et al. CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia. Cells. 2019;8(12):1580.
   PubMed Web of Science ®Google Scholar
• Gorczynski RM CD200:CD200R-Mediated Regulation of Immunity. ISRN Immunology 2012;2012:682168.
   Google Scholar
• Ho JM, Dobson SM, Voisin V, et al. CD200 expression marks leukemia stem cells in human AML. Blood Advances. 2020;4(21):5402–5413.
   PubMed Web of Science ®Google Scholar
• Kretz-Rommel A, Qin F, Dakappagari N, et al. Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy. The Journal of Immunology. 2008;180(2):699–705.
   PubMed Web of Science ®Google Scholar
• Herbrich S, Baran N, Cai T, et al. Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML. J Immunother Cancer. 2021;9(7):e002968.
   PubMed Web of Science ®Google Scholar
• Liu J, Wu Q, Shi J, et al. LILRB4, from the immune system to the disease target. Am J Transl Res. 2020;12(7):3149–3166.
   PubMed Web of Science ®Google Scholar
• Colonna M, Navarro F, Bellón T, et al. A Common Inhibitory Receptor for Major Histocompatibility Complex Class I Molecules on Human Lymphoid and Myelomonocytic Cells. Journal of Experimental Medicine. 1997;186(11):1809–1818.
   PubMed Web of Science ®Google Scholar
• Borges L, Hsu ML, Fanger N, et al. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. The Journal of Immunology. 1997;159(11):5192–5196.
   PubMed Web of Science ®Google Scholar
• Abdallah F, Coindre S, Gardet M, et al. Leukocyte Immunoglobulin-Like Receptors in Regulating the Immune Response in Infectious Diseases: A Window of Opportunity to Pathogen Persistence and a Sound Target in Therapeutics. Frontiers in Immunology. 2021;12:717998. 10.3389/fimmu.2021.717998
   PubMed Web of Science ®Google Scholar
• Kang X, Kim J, Deng M, et al. Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors. Cell Cycle. 2016;15(1):25–40.
   PubMed Web of Science ®Google Scholar
• Shaw AS, Timson LK, Zhu Y Interactions of TCR tyrosine based activation motifs with tyrosine kinases. Semin Immunol. 1995;7(1):13–20.
   PubMedGoogle Scholar
• Isakov N Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades. Journal of Leukocyte Biology. 1997;61(1):6–16.
   PubMed Web of Science ®Google Scholar
• van der Touw W, Chen H-M, Pan P-Y, et al. LILRB receptor-mediated regulation of myeloid cell maturation and function. Cancer Immunology, Immunotherapy. 2017;66(8):1079–1087.
   PubMed Web of Science ®Google Scholar
• Daeron M, Latour S, Malbec O, et al. The same tyrosine-based inhibition motif, in the intra-cytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity. 1995;3(5):635–646.
   PubMed Web of Science ®Google Scholar
• Cella M, Döhring C, Samaridis J, et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. Journal of Experimental Medicine. 1997;185(10):1743–1751.
   PubMed Web of Science ®Google Scholar
• Katz HR Inhibition of inflammatory responses by leukocyte Ig-like receptors. Adv Immunol. 2006;91:251–72.
   PubMed Web of Science ®Google Scholar
• Kim-Schulze S, Seki T, Vlad G, et al. Regulation of ILT3 gene expression by processing of precursor transcripts in human endothelial cells. American Journal of Transplantation. 2006;6(1):76–82.
   PubMed Web of Science ®Google Scholar
• Barkal AA, Weiskopf K, Kao KS, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology. 2018;19(1):76–84.
   PubMed Web of Science ®Google Scholar
• Deng M, Chen H, Liu X, et al. Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer. Antib Therap. 2021;4(1):16–33.
   PubMedGoogle Scholar
• Fleming V, Hu X, Weber R, et al. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. Front Immunol. 2018;9:398.
   PubMed Web of Science ®Google Scholar
• Deng M, Gui X, Kim J, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562(7728):605–609.
   PubMed Web of Science ®Google Scholar
• Tedla N, Lee CW, Borges L, et al. Differential expression of leukocyte immunoglobulin-like receptors on cord-blood-derived human mast cell progenitors and mature mast cells. J Leukoc Biol. 2008;83:334–43
   PubMed Web of Science ®Google Scholar
• Inui M, Hirota S, Hirano K, et al. Human CD43+ B cells are closely related not only to memory B cells phenotypically but also to plasmablasts developmentally in healthy individuals. Int Immunol. 2015;27:345–55.
   PubMed Web of Science ®Google Scholar
• Ulges A, Klein M, Reuter S, et al. Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo. Nat Immunol. 2015;16:267–75.
   PubMed Web of Science ®Google Scholar
• Mori Y, Tsuji S, Inui M, et al. Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development. J Immunol. 2008;181(7):4742–4751.
   PubMed Web of Science ®Google Scholar
• Cheng H, Mohammed F, Nam G, et al. Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3/LIR-5/CD85k): a myeloid inhibitory receptor involved in immune tolerance. J Biol Chem. 2011;286(20):18013–18025.
   PubMed Web of Science ®Google Scholar
• Su MT, Inui M, Wong YL, et al. Blockade of checkpoint ILT3/LILRB4/gp49B binding to fibronectin ameliorates autoimmune disease in BXSB/Yaa mice. Int Immunol. 2021;33:447–58.
   PubMed Web of Science ®Google Scholar
• Lu HK, Rentero C, Raftery MJ, et al. Leukocyte Ig-like receptor B4 (LILRB4) is a potent inhibitor of FcgammaRI-mediated monocyte activation via dephosphorylation of multiple kinases. J Biol Chem. 2009;284:34839–48.
   PubMed Web of Science ®Google Scholar
• Park M, Raftery MJ, Thomas PS, et al. Leukocyte immunoglobulin-like receptor B4 regulates key signalling molecules involved in FcgammaRI-mediated clathrin-dependent endocytosis and phagocytosis. Sci Rep. 2016;6:35085.
   PubMed Web of Science ®Google Scholar
• Manavalan JS, Kim-Schulze S, Scotto L, et al. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol. 2004;16:1055–1068.
   PubMed Web of Science ®Google Scholar
• Chang CC, Liu Z, Vlad G, et al. Ig-like transcript 3 regulates expression of proinflammatory cytokines and migration of activated T cells. J Immunol. 2009;182(9):5208–5216.
   PubMed Web of Science ®Google Scholar
• Li Z, Deng M, Huang F, et al. LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol Immunol. 2020;17(3):272–282.
   PubMed Web of Science ®Google Scholar
• Paavola KJ, Roda JM, Lin VY, et al. The fibronectin-ILT3 interaction functions as a stromal checkpoint that suppresses myeloid cells. Cancer Immunol Res. 2021;9:1283–97.
   PubMed Web of Science ®Google Scholar
• Gui X, Deng M, Song H, et al. Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development. Cancer Immunol Res. 2019;7(8):1244–1257.
   PubMed Web of Science ®Google Scholar
• John S, Chen H, Deng M, et al. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther. 2018;26:2487–95.
   PubMed Web of Science ®Google Scholar
• Anami Y, Deng M, Gui X, et al. LILRB4-targeting antibody-drug conjugates for the treatment of acute myeloid leukemia. Mol Cancer Ther. 2020;19:2330–9.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pollyea DA, Konopleva M, et al. A First-in-human (FIH) phase 1 study of the anti-LILRB4 antibody IO-202 in relapsed/refractory (R/R) myelomonocytic and monocytic acute myeloid leukemia (AML) and R/R chronic myelomonocytic leukemia (CMML). Blood. 2020;136(Supplement 1):19–20.
   Google Scholar
• Godal R, Bachanova V, Gleason M, et al. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant. 2010;16:612–21.
   PubMed Web of Science ®Google Scholar
• Wu G, Xu Y, Schultz RD, et al. LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2-cFLIP-NF-κB signaling axis. Nat Cancer. 2021;2(11):1170–1184.
   PubMedGoogle Scholar
• Kontermann RE, Brinkmann U Bispecific antibodies. Drug Discov Today. 2015;20(7):838–847.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE The making of bispecific antibodies. mAbs. 2017;9(2):182–212.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy A, Jimeno A Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. 2018;185:122–34.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608.
   PubMed Web of Science ®Google Scholar
• De Gast GC, Van Houten AA, Haagen IA, et al. Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies. J Hematother. 1995;4(5):433–437.
   PubMedGoogle Scholar
• Jen EY, Xu Q, Schetter A, et al. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease. Clin Cancer Res. 2019;25(2):473–477.
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123(4):554–561.
   PubMed Web of Science ®Google Scholar
• Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia. 2013;27(5):1107–1115.
   PubMed Web of Science ®Google Scholar
• Daver NG, Alotaibi AS, Bücklein V, et al. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35(7):1843–1863.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Walter RB, Subklewe M, et al. Updated Results from Phase I Dose-Escalation Study of AMG 330, a Bispecific T-Cell Engager Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). J Clin Oncol. 2020;38:7508.
   Web of Science ®Google Scholar
• Clark MC, Stein A CD33 directed bispecific antibodies in acute myeloid leukemia. Best Pract Res Clin Haematol. 2020;33(4):101224.
   PubMed Web of Science ®Google Scholar
• Subklewe M, Stein A, Walter RB, et al. Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Blood. 2019;134:833.
   Web of Science ®Google Scholar
• Westervelt P, Roboz GJ, Cortes JE, et al. Phase 1 first-in-human Trial of AMV564, a bivalent bispecific (2x2) CD33/CD3 T-cell engager, in patients with relapsed/refractory acute myeloid leukemia (AML). Blood. 2018;132(Supplement 1):1455.
   PubMedGoogle Scholar
• Guy DG, Uy GL Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. Curr Hematol Malig Rep. 2018;13(6):417–425.
   PubMed Web of Science ®Google Scholar
• Nair-Gupta P, Diem M, Reeves D, et al. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia. Blood Adv. 2020;4(5):906–919.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Bashey A, Stock W, et al. Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XMAB14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study. Blood. 2020;136(Supplement 1):4–5.
   PubMed Web of Science ®Google Scholar
• Moore PA, Zhang W, Rainey GJ, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood. 2011;117:4542–51.
   PubMed Web of Science ®Google Scholar
• Isidori A, Cerchione C, Daver NG, et al. Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Front Oncol. 2021;11:656218.
   PubMedGoogle Scholar
• Uy GL, Aldoss I, Foster MC, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137(6):751–762.
   PubMed Web of Science ®Google Scholar
• Alderson RF, Huang L, Zhang X, et al. Combinatorial Anti-Tumor Activity in Animal Models of a Novel CD123 x CD3 Bispecific Dart® Molecule (MGD024) with Cytarabine, Venetoclax or Azacitidine Supports Combination Therapy in Acute Myeloid Leukemia. Blood. 2021;138(Supplement 1):1165.
   Google Scholar
• Comeau MR, Miller RE, Bader R, et al. APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release. Cancer Res. 2018;78(13_Supplement):Abstract 1786.
   Web of Science ®Google Scholar
• Watts J, Lin TL, Mims A, et al. Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA. Front Oncol. 2022;11:806243.
   PubMed Web of Science ®Google Scholar
• de Silva S, Fromm G, Shuptrine CW, et al. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity. Cancer Immunol Res. 2010;8(2):230–245.
   Google Scholar
• Cendrowicz E, Jacob L, Greenwald S, et al. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity. J Exp Clin Cancer Res. 2022;41(1):97.
   PubMed Web of Science ®Google Scholar
• Leong SR, Sukumaran S, Hristopoulos M, et al. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. Blood. 2017;129(5):609–618.
   PubMed Web of Science ®Google Scholar
• van Loo PF, Hangalapura BN, Thordardottir S, et al. MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019;19(7):721–733.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Huls G, Venditti A, et al. Update from the ongoing phase I multinational study of MCLA-117, a bispecific CLEC12A x CD3 T-cell engager, in patients (pts) with acute myelogenous leukemia (AML). Eur Hematol Assoc Meeting. 2020;25:538.
   Google Scholar
• Lim Y, Lee E, Lee S, et al. A Novel Asymmetrical Anti-CLL-1×CD3 Bispecific Antibody, ABL602, Induces Potent CLL1-Specific Antitumor Activity with Minimized Sensitization of Pro-Inflammatory Cytokines. Blood. 2021;138(Supplement 1):2234.
   Google Scholar
• Brauchle B, Goldstein RL, Karbowski CM, et al. Characterization of a novel FLT3 BiTE molecule for the treatment of acute myeloid leukemia. Mol Cancer Ther. 2020;19:1875–88.
   PubMed Web of Science ®Google Scholar
• Mehta NK, Pfluegler M, Meetze K, et al. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL. J Immunother Cancer. 2022;10(e003882).
   PubMedGoogle Scholar
• Surveillance, Epidemiology, and End Results (SEER) SEER*Stat Database: Acute Myeloid Leukemia — Cancer Stat Facts. U. S. National Institutes of Health, National Cancer Institute. Cited 2022 Nov 29. https://seer.cancer.gov
   Google Scholar
• Vallera DA, Felices M, McElmurry R, et al. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res. 2016;22(14):3440–3450.
   PubMed Web of Science ®Google Scholar